Defining the Criteria of What Makes a Good Target

10:20 am Chair’s Opening Remarks

10:30 am Immune-Stimulating Antibody Conjugates Targeting CEA & PD-L1 for Cancer Therapy

  • Bill Mallet Staff Scientist, Target Validation Bolt Bio


  • We have many good targets but no perfect ones – review some key steps to building a strong target validation package
  • Every target has a liability – understand what we can tolerate, what we should avoid, and when our assumptions should be put aside
  • Evaluate case studies including target validation for cytotoxic ADCs and immunotherapies

11:00 am Virtual Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC Targets field and establish meaningful business relationships to pursue for the rest of the conference.

Looking at Novel Targets & The Future of Targets for ADCs

12:00 pm Targeting EGFR Through ADCs


  • Delving into the history of this target
  • Understanding the lessons learned from working on this target
  • Looking into future perspectives

12:30 pm Targeting Leukaemias with Anti-CD7 Antibody & ADC

1:00 pm Lunch & Networking

Exploring the Target-Payload Selection

2:00 pm Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug

Exploring the Target-Payload Selection

2:30 pm Target Expression & Warhead: The Driving Forces of ADC Activity


  • How much target expression is needed for ADC activity?
  • Do we know the correlation between level of expression and payload type?
  • Could testing ADC activity in 3D tumor organoid systems give better clinical translation in terms of ADC activity as related to target expression and payload?

3:00 pm Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induces Potent Anti- Tumor Immunity

  • Tracy Kuo Senior Director - Biology & Translational Science, Tallac Therapeutics


  • Identify how activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides promotes innate inflammatory responses and induction of adaptive immunity
  • Review our novel Toll-Like Receptor Agonist Antibody Conjugate (TRAAC) platform developed to deliver a potent TLR9 (T-CpG agonist for targeted immune activation via systemic administration
  • Evaluate various TRAAC approaches targeting either immune cell receptor or tumor specific antigens in preclinical settings

3:30 pm Chair’s Closing Remarks